• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CHU Xuxin, BU Fanxue, YIN Tingjie, HUO Meirong. Antitumor strategies based on targeted modulation of tumor-associated macrophages[J]. Journal of China Pharmaceutical University, 2021, 52(3): 261-269. DOI: 10.11665/j.issn.1000-5048.20210301
Citation: CHU Xuxin, BU Fanxue, YIN Tingjie, HUO Meirong. Antitumor strategies based on targeted modulation of tumor-associated macrophages[J]. Journal of China Pharmaceutical University, 2021, 52(3): 261-269. DOI: 10.11665/j.issn.1000-5048.20210301
shu

Antitumor strategies based on targeted modulation of tumor-associated macrophages

  • Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Funds: This work was supported by the National Natural Science Foundation of China (No.82073175, No.81972835, No.81872424, No.81703442) and Qing-Lan Project of Jiangsu Province
More Information
  • Received Date: March 06, 2021
  • Revised Date: April 29, 2021
    Graphical Abstract
    • Abstract
  • Tumor-associated macrophages (TAMs) are the most abundant innate immune cells in tumors, which generally exhibit anti-inflammatory M2 phenotypes, and are the key inducers of tumor development, metastasis and drug resistance, and thus becoming a popular target in the field of antitumor immunotherapy.The study and application of nanocarriers optimize TAMs-targeted antitumor therapy.According to the characteristics and functions of TAMs, modulation strategies based on TAMs are elaborated, including TAMs depletion, inhibition of TAMs recruitment and TAMs repolarization.At the same time, in order to apply the above strategies more efficiently and overcome the general off-target problems in treatment, specific TAMs-targeted therapies based on nanocarriers are reviewed and analyzed, including passive targeting to TAMs, active targeting to macrophages and specifically active targeting to M2-TAMs. Finally, based on the limitations of targeting TAMs alone, new therapeutic strategies of targeting both TAMs and tumor cells via nanocarrier based delivery systems are introduced to provide new ideas for the application of these strategies in the field of tumor immunotherapy and combination therapy with other antitumor strategies.
    • FullText(HTML)
    • References (65)
  • [1]
    . J China Pharm Univ（中国药科大学学报），2018，49（1）：20-25.
    [2]
    Bian XJ，Xiao YT，Wu TQ，et al. Microvesicles and chemokines in tumor microenvironment：mediators of intercellular communications in tumor progression［J］. Mol Cancer，2019，18（1）：50.
    [3]
    Brassart-Pasco S，Brézillon S，Brassart B，et al. Tumor microenvironment：extracellular matrix alterations influence tumor progression［J］. Front Oncol，2020，10：397.
    [4]
    Novikova MV，Khromova NV，Kopnin PB. Components of the hepatocellular carcinoma microenvironment and their role in tumor progression［J］. Biochemistry （Mosc），2017，82（8）：861-873.
    [5]
    Dehne N，Mora J，Namgaladze D，et al. Cancer cell and macrophage cross-talk in the tumor microenvironment［J］. Curr Opin Pharmacol，2017，35：12-19.
    [6]
    Bi L，Gao J，Jiang YC，et al. Effect of Ginseng，Ginseng polysaccharides and Ginsenoside on the human lung cancer cells A549 in co-culture system of TAMs with A549 cells［J］. J China Pharm Univ（中国药科大学学报），2016，47（6）：744-748.
    [7]
    Yang L，Zhang Y. Tumor-associated macrophages：from basic research to clinical application［J］. J Hematol Oncol，2017，10（1）：58.
    [8]
    Jeannin P，Paolini L，Adam C，et al. The roles of CSFs on the functional polarization of tumor-associated macrophages［J］. FEBS J，2018，285（4）：680-699.
    [9]
    Jayasingam SD，Citartan M，Thang TH，et al. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue：technicalities and challenges in routine clinical practice［J］. Front Oncol，2019，9：1512.
    [10]
    Binnemars-Postma K，Storm G，Prakash J. Nanomedicine strategies to target tumor-associated macrophages［J］. Int J Mol Sci，2017，18（5）：E979.
    [11]
    Petty AJ，Yang YP. Tumor-associated macrophages：implications in cancer immunotherapy［J］. Immunotherapy，2017，9（3）：289-302.
    [12]
    Chen XJ，Wu S，Yan RM，et al. The role of the hypoxia-Nrp-1 axis in the activation of M2-like tumor-associated macrophages in the tumor microenvironment of cervical cancer［J］. Mol Carcinog，2019，58（3）：388-397.
    [13]
    Lin YX，Xu JX，Lan HY. Tumor-associated macrophages in tumor metastasis：biological roles and clinical therapeutic applications［J］. J Hematol Oncol，2019，12（1）：76.
    [14]
    Chen YB，Song YC，Du W，et al. Tumor-associated macrophages：an accomplice in solid tumor progression［J］. J Biomed Sci，2019，26（1）：78.
    [15]
    Laviron M，Boissonnas A. Ontogeny of tumor-associated macrophages［J］. Front Immunol，2019，10：1799.
    [16]
    Malfitano AM，Pisanti S，Napolitano F，et al. Tumor-associated macrophage status in cancer treatment［J］. Cancers，2020，12（7）：1987.
    [17]
    Cui Y，Guo G. Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment［J］. Int J Mol Sci，2016，17（11）：1942.
    [18]
    Cassetta L，Pollard JW. Targeting macrophages：therapeutic approaches in cancer［J］. Nat Rev Drug Discov，2018，17（12）：887-904.
    [19]
    Li X，Liu R，Su X，et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy［J］. Mol Cancer，2019，18（1）：177.
    [20]
    O'Brien SA，Orf J，Skrzypczynska KM，et al. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment［J］. Cancer Immunol Immunother，2021. doi：10.1007/s00262-021-02861-3.
    [21]
    Cannarile MA，Weisser M，Jacob W，et al. Colony-stimulating factor 1 receptor （CSF1R） inhibitors in cancer therapy［J］. J Immunother Cancer，2017，5（1）：53.
    [22]
    Ries CH，Cannarile MA，Hoves S，et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy［J］. Cancer Cell，2014，25（6）：846-859.
    [23]
    Billington EO，Reid IR. Benefits of bisphosphonate therapy：beyond the skeleton［J］. Curr Osteoporos Rep，2020，18（5）：587-596.
    [24]
    Andón FT，Digifico E，Maeda A，et al. Targeting tumor associated macrophages：The new challenge for nanomedicine［J］. Semin Immunol，2017，34：103-113.
    [25]
    Phuengkham H，Ren L，Shin IW，et al. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy［J］. Adv Mater，2019，31（34）：e1803322.
    [26]
    Singh Y，Pawar VK，Meher JG，et al. Targeting tumor associated macrophages （TAMs） via nanocarriers［J］. J Control Release，2017，254：92-106.
    [27]
    Ngambenjawong C，Gustafson HH，Pun SH. Progress in tumor-associated macrophage （TAM）-targeted therapeutics［J］. Adv Drug Deliv Rev，2017，114：206-221.
    [28]
    Zang X，Zhang X，Hu H，et al. Targeted delivery of zoledronate to tumor-associated macrophages for cancer immunotherapy［J］. Mol Pharm，2019，16（5）：2249-2258.
    [29]
    Goswami KK，Ghosh T，Ghosh S，et al. Tumor promoting role of anti-tumor macrophages in tumor microenvironment［J］. Cell Immunol，2017，316：1-10.
    [30]
    Argyle D，Kitamura T. Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors［J］. Front Immunol，2018，9：2629.
    [31]
    Nywening TM，Wang-Gillam A，Sanford DE，et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer：a single-centre，open-label，dose-finding，non-randomised，phase 1b trial［J］. Lancet Oncol，2016，17（5）：651-662.
    [32]
    Shapouri-Moghaddam A，Mohammadian S，Vazini H，et al. Macrophage plasticity，polarization，and function in health and disease［J］. J Cell Physiol，2018，233（9）：6425-6440.
    [33]
    Ruytinx P，Proost P，van Damme J，et al. Chemokine-induced macrophage polarization in inflammatory conditions［J］. Front Immunol，2018，9：1930.
    [34]
    Pathria P，Louis TL，Varner JA. Targeting tumor-associated macrophages in cancer［J］. Trends Immunol，2019，40（4）：310-327.
    [35]
    Veillette A，Chen J. SIRPα-CD47 immune checkpoint blockade in anticancer therapy［J］. Trends Immunol，2018，39（3）：173-184.
    [36]
    Weiskopf K，Jahchan NS，Schnorr PJ，et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer［J］. J Clin Invest，2016，126（7）：2610-2620.
    [37]
    Feng Y，Mu R，Wang Z，et al. A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages［J］. Nat Commun，2019，10（1）：2272.
    [38]
    Rodríguez-Ruiz ME，Perez-Gracia JL，Rodríguez I，et al. Combined immunotherapy encompassing intratumoral poly-ICLC，dendritic-cell vaccination and radiotherapy in advanced cancer patients［J］. Ann Oncol，2018，29（5）：1312-1319.
    [39]
    Georgoudaki AM，Prokopec KE，Boura VF，et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis［J］. Cell Rep，2016，15（9）：2000-2011.
    [40]
    Locatelli SL，Careddu G，Serio S，et al. Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530［J］. Clin Cancer Res，2019，25（3）：1098-1112.
    [41]
    Guerriero JL，Sotayo A，Ponichtera HE，et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages［J］. Nature，2017，543（7645）：428-432.
    [42]
    Chen Q，Wang C，Zhang X，et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment［J］. Nat Nanotechnol，2019，14（1）：89-97.
    [43]
    Song K，Pan H，Han JY，et al. Nano drug delivery system based strategies to target tumor microenvironment［J］. J China Pharm Univ（中国药科大学学报），2018，49（4）：392-400.
    [44]
    Dai W，Wang X，Song G，et al. Combination antitumor therapy with targeted dual-nanomedicines［J］. Adv Drug Deliv Rev，2017，115：23-45.
    [45]
    La-Beck NM，Liu XL，Shmeeda H，et al. Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment［J］. Semin Cancer Biol，2021，68：175-185.
    [46]
    Wakaska RR. Challenges pertaining to adverse effects of drugs［J］. Int J Drug Dev Res，2017，9（1）：1-2.
    [47]
    An YY，Yang Q. Tumor-associated macrophage-targeted therapeutics in ovarian cancer［J］. Int J Cancer，2020. doi：10.1002/ijc.33408.
    [48]
    Zang XL，Zhang XX，Zhao XL，et al. Targeted delivery of miRNA 155 to tumor associated macrophages for tumor immunotherapy［J］. Mol Pharm，2019，16（4）：1714-1722.
    [49]
    Sun X，Gao D，Gao L，et al. Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer［J］. Theranostics，2015，5（6）：597-608.
    [50]
    Tie Y，Zheng H，He ZY，et al. Targeting folate receptor β positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex［J］. Signal Transduct Target Ther，2020，5（1）：6.
    [51]
    Hattori Y，Yamashita J，Sakaida C，et al. Evaluation of antitumor effect of zoledronic acid entrapped in folate-linked liposome for targeting to tumor-associated macrophages［J］. J Liposome Res，2015，25（2）：131-140.
    [52]
    Weiskopf K，Anderson KL，Ito D，et al. Eradication of canine diffuse large B-cell lymphoma in a murine xenograft model with CD47 blockade and anti-CD20［J］. Cancer Immunol Res，2016，4（12）：1072-1087.
    [53]
    Franklin RA，Liao W，Sarkar A，et al. The cellular and molecular origin of tumor-associated macrophages［J］. Science，2014，344（6186）：921-925.
    [54]
    Lin Y，Wei C，Liu Y，et al. Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis［J］. Cancer Sci，2013，104（9）：1217-1225.
    [55]
    Kang T，Jiang MY，Jiang D，et al. Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex［J］. Mol Pharm，2015，12（8）：2947-2961.
    [56]
    Qian Y，Qiao S，Dai YF，et al. Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages［J］. ACS Nano，2017，11（9）：9536-9549.
    [57]
    Peng H，Wang JH，Guo F，et al. Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and cancer chemotherapy［J］. Colloids Surf B Biointerfaces，2021，197：111442.
    [58]
    Cieslewicz M，Tang JJ，Yu JL，et al. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival［J］. Proc Natl Acad Sci U S A，2013，110（40）：15919-15924.
    [59]
    Pang L，Pei YH，Uzunalli G，et al. Surface modification of polymeric nanoparticles with M2pep peptide for drug delivery to tumor-associated macrophages［J］. Pharm Res，2019，36（4）：65.
    [60]
    Brahmer JR，Tykodi SS，Chow LQ，et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer［J］. N Engl J Med，2012，366（26）：2455-2465.
    [61]
    Wu XL，Wu YD，Ye HB，et al. Interleukin-15 and cisplatin co-encapsulated thermosensitive polypeptide hydrogels for combined immuno-chemotherapy［J］. J Control Release，2017，255：81-93.
    [62]
    Chen J，Dou Y，Tang Y，et al. Folate receptor-targeted RNAi nanoparticles for silencing STAT3 in tumor-associated macrophages and tumor cells［J］. Nanomedicine，2020，25：102173.
    [63]
    Conde J，Bao CC，Tan YQ，et al. Dual targeted immunotherapy via in vivo delivery of biohybrid RNAi-peptide nanoparticles to tumour-associated macrophages and cancer cells［J］. Adv Funct Mater，2015，25（27）：4183-4194.
    [64]
    Sylvestre M，Crane CA，Pun SH. Progress on modulating tumor-associated macrophages with biomaterials［J］. Adv Mater，2020，32（13）：e1902007.
    [65]
    Yang QY，Guo NN，Zhou Y，et al. The role of tumor-associated macrophages （TAMs） in tumor progression and relevant advance in targeted therapy［J］. Acta Pharm Sin B，2020，10（11）：2156-2170.
    • Related Articles

  • Related Articles

    [1]WANG Jiang, ZHAO Xueyan, FANG Weirong. Research progress in STAT3/Th17 cells and Sjögren syndrome[J]. Journal of China Pharmaceutical University, 2024, 55(3): 420-428. DOI: 10.11665/j.issn.1000-5048.2023041805
    [2]SHI Xiaoni, YANG Shaoqi, CHENG Yusi, CHAO Jie. PPP2R3A promotes silicosis by regulating the expression of p53[J]. Journal of China Pharmaceutical University, 2022, 53(4): 490-497. DOI: 10.11665/j.issn.1000-5048.20220412
    [3]LIU Li, ZHANG Qianwen, NONG Cheng, ZHANG Xi, XU Xiaoting, Mohammed Ismail, XIAO Li, JIANG Zhenzhou, ZHANG Luyong, SUN Lixin. Research progress of lncRNA regulating signal transduction pathway in liver diseases[J]. Journal of China Pharmaceutical University, 2020, 51(3): 277-286. DOI: 10.11665/j.issn.1000-5048.20200304
    [4]WAN Nanyan, JIANG Cuihua, GAO Meng, ZHANG Jian, YIN Zhiqi, PAN Ke. Paeoniflorin inhibits programmed cell death-1-ligand 1 expression in HepG2 cells by regulating JAK/STAT3 signal pathway[J]. Journal of China Pharmaceutical University, 2019, 50(2): 213-221. DOI: 10.11665/j.issn.1000-5048.20190213
    [5]QIAO Jianan, WANG Tingfang, ZHANG Can. Design, synthesis and bioactivities of 4-(3-sulfonylbenzene)amino-6-formylpyrrole［2, 3-d］ pyrimidine derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(5): 554-562. DOI: 10.11665/j.issn.1000-5048.20170508
    [6]TAN Chengning, HUANG Jinghan, LI Chunhong, XIA Zhining, YANG Fengqing. Applications of proteomics in the study of cell signal pathways[J]. Journal of China Pharmaceutical University, 2017, 48(4): 384-395. DOI: 10.11665/j.issn.1000-5048.20170402
    [7]LIU Xiaofei, WANG Tingfang, JU Caoyun, ZHANG Can. Synthesis and JAK2 inhibitory activities of 4-phenyl-pyrrolo［2, 3-d］pyrimidine derivatives[J]. Journal of China Pharmaceutical University, 2017, 48(2): 150-156. DOI: 10.11665/j.issn.1000-5048.20170204
    [8]WANG Jing-song, SHEN Jing, ZHANG Ting, TANG Cong, REN Tian-nian, XI Tao. Ursolic acid downregulates COX-2 expression by suppressing the activation of ERK in A549 cells[J]. Journal of China Pharmaceutical University, 2011, 42(1): 68-72.
    [9]Changes of Expression and Functions of Dipeptide Transporter after Anoxia/reoxygenation in Caco-2 Cells[J]. Journal of China Pharmaceutical University, 2003, (1): 76-79.
    [10]Effects of 3 Tyrphostins on Recombinant Human Protein Kinase CK2 Holoenzyme[J]. Journal of China Pharmaceutical University, 2001, (6): 51-56.

  • Cited by

    Periodical cited type(6)

    1. 朱秋梦，石佳琦，吕玮，张昕，肖云峰. 丁香酚对大鼠心肌缺血再灌注损伤的抑制作用及其机制. 山东医药. 2024(05): 7-11 .
    2. 张艺馨，李双. 依托咪酯调控circ-CCND1/miR-214-5p分子轴减轻缺氧/复氧诱导的心肌细胞损伤. 中国药师. 2022(01): 6-11 .
    3. 徐季轩，马晓静，陈泓颖，高小力，佟海英，屠鹏飞，安超，柴兴云. 我国主要少数民族医药防治缺血性心脏病研究概述. 中国实验方剂学杂志. 2022(17): 235-247 .
    4. 赵汴霞，宛蕾. 人参皂苷Rd对人脐静脉内皮细胞凋亡保护的作用研究. 河南医学高等专科学校学报. 2022(04): 399-405 .
    5. 劳慧敏，李燕宁，韩成恩，陈梦琦. 养心活血解毒方对CVB3诱导的病毒性心肌炎小鼠心肌损伤的保护作用. 时珍国医国药. 2021(03): 544-547 .
    6. 张文超，方秧青，钟静红，张明. 粉防己碱通过JAK2-STAT3途径减轻心肌缺血/再灌注损伤. 解剖学杂志. 2021(04): 291-294+318 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (789) PDF downloads (1094) Cited by(8)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：292781

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return